.jpg?format=webp&quality=80&width=3840)
A live recombinant Newcastle disease virus (NDV) vaccine candidate, NDV-HXP-S, has shown potential in stopping the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine expresses a stable spike protein on infected cells and viral particles, allowing for effective immune response. It can be grown in embryonated eggs at a low cost and administered intranasally, potentially inducing mucosal immunity. In a phase I clinical trial involving 91 volunteers in Mexico, the vaccine was found to be safe and immunogenic when given via different regimens. This positive outcome supports further development of the vaccine candidate for COVID-19 prevention.
Like
Save
Share